RxDoctor Payments Data

Clay Lyddane, MD

Urology · Wichita, KSNPI 1760641476

Payments from drug & device makers

$530in general payments, 2019–2025

Across 36 payments — averaging $14.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$132
  • C. R. Bard, Inc. & Subsidiaries$80
  • Rochester Medical Corporation$74
  • Coloplast$49
  • Boston Scientific$38
  • AbbVie$35
  • plus $121 from 5 others

What the payments were for

  • Food & beverage$51898%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer11$132
C. R. Bard, Inc. & Subsidiaries5$80
Rochester Medical Corporation5$74
Coloplast4$49
Boston Scientific1$38
AbbVie(2 entities)2$35
Astellas Pharma US Inc2$29
Amgen2$27
Travere Therapeutics, Inc.2$25
Endo USA, Inc.1$21
Antares Pharma, Inc.1$19

How this compares

$530 in reported general payments places this provider in the 20th percentile of 111 urology providers in Kansas.

See all urology providers in Kansas

Medicare billing

Part B allowed, 2024
$104,704
Medicare patients
366
Services billed
1,291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron91$58,170
GemtesaVibegron52$35,881
Tamsulosin Hcl847$11,533
Trimethoprim76$4,171
Oxybutynin Chloride202$2,516
Estradiol39$2,388
Finasteride122$1,209
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst53$924
Oxybutynin Chloride ErOxybutynin Chloride50$660
Alfuzosin Hcl ErAlfuzosin Hcl53$466
Solifenacin Succinate14$440
Tadalafil12$422
Ciprofloxacin Hcl64$277
Cephalexin15$186
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen38$179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$29$58,17091 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 111 urology providers in Kansas.

Other urology in Wichita

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →